COVID-19 in solid organ transplant recipients: a single-center experience

Research output: Contribution to journalArticleAcademicpeer-review

65 Citations (Scopus)


Solid organ transplant (SOT) recipients may be at risk for severe COVID-19. Data on the clinical course of COVID-19 in immunosuppressed patients are limited, and the effective treatment strategy for these patients is unknown. We describe our institutional experience with COVID-19 in SOT. Demographic, clinical, and treatment data were extracted from the electronic patient files. A total of 23 SOT transplant recipients suffering from COVID-19 were identified (n = 3 heart; n = 15 kidney; n = 1 kidney-after-heart; n = 3 lung, and n = 1 liver transplant recipient). The presenting symptoms were similar to nonimmunocompromised patients. Eighty-three percent (19/23) of the patients required hospitalization, but only two of these were transferred to the intensive care unit. Five patients died from COVID-19; all had high Clinical Frailty Scores. In four of these patients, mechanical ventilation was deemed futile. In 57% of patients, the immunosuppressive therapy was not changed and only three patients were treated with chloroquine. Most patients recovered without experimental antiviral therapy. Modification of the immunosuppressive regimen alone could be a therapeutic option for SOT recipients suffering from moderate to severe COVID-19. Pre-existent frailty is associated with death from COVID-19.

Original languageEnglish
Pages (from-to)1099-1105
Number of pages7
JournalTransplant International
Issue number9
Publication statusPublished - Sept 2020

Bibliographical note

Publisher Copyright:
© 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd

Research programs

  • EMC COEUR-09
  • EMC MM-04-20-01
  • EMC MM-04-42-02


Dive into the research topics of 'COVID-19 in solid organ transplant recipients: a single-center experience'. Together they form a unique fingerprint.

Cite this